| Theme | Management of osteoporosis : an update | |
|---|---|---|
| Title | Medical treatment of osteoporosis | |
| Publish Date | 2017/03 | |
| Author | Nobuyuki Tai | Third Department of Medicine, Teikyo University Chiba Medical Center |
| Author | Daisuke Inoue | Third Department of Medicine, Teikyo University Chiba Medical Center |
| [ Summary ] | Drugs with different mechanisms of action, such as anti-RANKL antibodies and parathyroid hormone, have been introduced in the past decade to treat osteoporosis. Once-yearly zoledronic acid was also approved in Japan in 2016. The diversification of therapeutic drugs has enabled us to provide customized treatments for the treatment of osteoporosis. However, as a result, drug selection criteria have become complicated. New tasks have emerged due to the introduction of new drugs. One new task is checking on rebound phenomenon after discontinuation. Clinical trials have shown that bone mineral density decreases rapidly after discontinuation of anti-RANKL antibody therapy and parathyroid hormone treatment. Consequently, sequential therapy is required in most cases after discontinuation. In this article, we outline the features of each drug and the keys to drug selection. | |